Q3 25 EPS
$-0.95
MISS 22.31%
Est. $-0.78
Q3 25 Revenue
$120.7M
BEAT +14.23%
Est. $105.7M
vs S&P Since Q3 25
-1.1%
TRAILING MARKET
BBIO +6.7% vs S&P +7.9%
Market Reaction
Did BBIO Beat Earnings? Q3 2025 Results
BridgeBio Pharma delivered a mixed Q3 2025 report, posting revenue that cleared Wall Street's bar while earnings fell short, as the company's explosive Attruby commercial launch collided with the heavy costs of building a multi-product genetic medici… Read more BridgeBio Pharma delivered a mixed Q3 2025 report, posting revenue that cleared Wall Street's bar while earnings fell short, as the company's explosive Attruby commercial launch collided with the heavy costs of building a multi-product genetic medicine franchise. Revenue surged to $120.70 million, a staggering 4,318% jump year-over-year and well above the $105.67 million consensus, driven almost entirely by $108.11 million in U.S. Net product sales of Attruby for ATTR-CM, a drug that generated zero revenue in the year-ago period. On the bottom line, however, BridgeBio missed, reporting a loss of $0.95 per share against the $0.78 consensus estimate, a 22.31% shortfall, as SG&A expenses climbed $68.80 million to fund the launch and noncash interest charges on a new royalty monetization deal added $36.41 million in costs. The pipeline simultaneously delivered registrational wins, with BBP-418 and encaleret both meeting Phase 3 primary endpoints; BridgeBio plans NDA filings for both programs in the first half of 2026, a pipeline cadence that echoes momentum seen across rare disease peers this earnings season.
Key Takeaways
- • Strong Attruby commercial launch with 5,259 unique patient prescriptions by 1,355 unique prescribers since FDA approval in November 2024
- • Accelerating growth in treatment-naïve patient segment
- • Attruby clinical differentiation with JACC publication showing cardiovascular outcome benefits within first month of treatment
- • 49% hazard reduction in cardiovascular mortality or recurrent cardiovascular-related hospitalizations at Month 30 versus placebo
- • Royalty revenue from BEYONTTRA sales in EU and Japan
BBIO YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
BBIO Revenue by Segment
With YoY comparisons, source: SEC Filings
“Attruby's strong commercial performance continues to validate our model, delivering a potential best-in-class medicine to patients who were historically overlooked and building meaningful momentum across all market segments. We are now seeing that same success echoed in our pipeline with home-run data in both ADH1 and LGMD2I/R9, and we continue to advance one of the broadest and fastest-moving portfolios in genetic medicine.”
— Neil Kumar, Q3 2025 Earnings Press Release
BBIO Earnings Trends
BBIO vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BBIO EPS Trend
Earnings per share: estimate vs actual
BBIO Revenue Trend
Quarterly revenue: estimate vs actual
BBIO Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $-0.62 | $-0.84 | -36.21% | $194.5M | +8.90% |
| Q4 25 MISS FY | $-0.62 | $-1.00 | -60.44% | $154.2M | +3.42% |
| FY Full Year | $-3.19 | $-3.78 | -18.50% | $502.1M | +0.91% |
| Q3 25 MISS | $-0.78 | $-0.95 | -22.31% | $120.7M | +14.23% |
| Q2 25 MISS | $-0.61 | $-0.95 | -57.02% | $110.6M | +24.54% |
| Q1 25 BEAT | $-1.00 | $-0.88 | +11.78% | $116.6M | +102.06% |